Skip to main content
Top
Published in: European Journal of Nutrition 3/2018

01-04-2018 | Original Contribution

Effects of tryptophan-containing peptides on angiotensin-converting enzyme activity and vessel tone ex vivo and in vivo

Authors: Sherif Khedr, Andreas Deussen, Irakli Kopaliani, Birgit Zatschler, Melanie Martin

Published in: European Journal of Nutrition | Issue 3/2018

Login to get access

Abstract

Purpose

Over-activation of the renin-angiotensin axis and worsening of vascular function are critical contributors to the development of hypertension. Therefore, inhibition of angiotensin-converting enzyme (ACE), a key factor of the renin-angiotensin axis, is a first line treatment of hypertension. Besides pharmaceutical ACE inhibitors, some natural peptides have been shown to exert ACE-inhibiting properties with antihypertensive effects and potentially beneficial effects on vascular function. In this study, the ACE-inhibiting potential and effects on vascular function of tryptophan-containing peptides were evaluated.

Methods

The ACE inhibitory action and stability of tryptophan-containing peptides was tested in endothelial cells—a major source of whole body ACE activity. Furthermore, the efficacy of peptides on vascular ACE activity, as well as vessel tone was assessed both ex vivo and in vivo.

Results

In human umbilical vein endothelial cells (HUVEC), isoleucine-tryptophan (IW) had the highest ACE inhibitory efficacy, followed by glutamic acid-tryptophan (EW) and tryptophan-leucine (WL). Whereas none of the peptides affected basal vessel tone (rat aorta), angiotensin I-induced vasoconstriction was blocked. IW effectively inhibited aortic ACE activity ex vivo taken from SHRs after 14-weeks of oral treatment with IW. Furthermore, IW treated SHRs showed better endothelium-dependent vessel relaxation compared to placebo.

Conclusion

This study shows strong ACE-inhibiting effects of IW, EW and WL in HUVECs and aorta. The peptides effectively counteract angiotensin-induced vasoconstriction and preserve endothelium-dependent vessel relaxation. Thus, tryptophan-containing peptides and particularly IW may serve as innovative food additives with the goal of protection from angiotensin II-induced worsening of vascular function.
Literature
1.
go back to reference Foex P, Sear J (2004) Hypertension: pathophysiology and treatment. Contin Educ Anaesth Cirt Care Pain 4:71–75CrossRef Foex P, Sear J (2004) Hypertension: pathophysiology and treatment. Contin Educ Anaesth Cirt Care Pain 4:71–75CrossRef
2.
go back to reference Akpunonu BE, Mulrow PJ, Hoffman EA (1996) Secondary hypertension: evaluation and treatment. Dis Mon 42(10):609–722CrossRef Akpunonu BE, Mulrow PJ, Hoffman EA (1996) Secondary hypertension: evaluation and treatment. Dis Mon 42(10):609–722CrossRef
3.
go back to reference Fanelli C, Zatz R (2011) Linking oxidative stress, the renin-angiotensin system and hypertension. Hypertension 57:373–374CrossRef Fanelli C, Zatz R (2011) Linking oxidative stress, the renin-angiotensin system and hypertension. Hypertension 57:373–374CrossRef
4.
go back to reference Atlas SA (2007) The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 13(8 Suppl B):9–20 Atlas SA (2007) The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 13(8 Suppl B):9–20
5.
go back to reference Brown NJ, Vaughan DE (1998) Angiotensin-converting enzyme inhibitors. Circulation 97:1411–1420CrossRef Brown NJ, Vaughan DE (1998) Angiotensin-converting enzyme inhibitors. Circulation 97:1411–1420CrossRef
6.
go back to reference Ishiguro K, Hayashi K, Sasamura H, Sakamaki Y, Itoh H (2009) “Pulse” treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension. Hypertension 53:83–89CrossRef Ishiguro K, Hayashi K, Sasamura H, Sakamaki Y, Itoh H (2009) “Pulse” treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension. Hypertension 53:83–89CrossRef
7.
go back to reference Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Aldo P, Maggioni MD, Solomon S, Swedberg K, Van de Werf F, White H et al (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906CrossRef Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Aldo P, Maggioni MD, Solomon S, Swedberg K, Van de Werf F, White H et al (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906CrossRef
8.
go back to reference Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572CrossRef Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572CrossRef
10.
go back to reference Korhonen H, Pihlanto A (2006) Bioactive peptides: production and functionality. Int Dairy J 16:945–996CrossRef Korhonen H, Pihlanto A (2006) Bioactive peptides: production and functionality. Int Dairy J 16:945–996CrossRef
11.
go back to reference Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T (1995) Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 78:777–783CrossRef Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T (1995) Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 78:777–783CrossRef
12.
go back to reference Nakamura T, Mizutani J, Ohki K, Yamada K, Yamamoto N, Takeshi M, Takazawa K (2011) Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: a randomized, double-blind, placebo-controlled trial. Atherosclerosis 219:298–303CrossRef Nakamura T, Mizutani J, Ohki K, Yamada K, Yamamoto N, Takeshi M, Takazawa K (2011) Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: a randomized, double-blind, placebo-controlled trial. Atherosclerosis 219:298–303CrossRef
13.
go back to reference Jäkälä P, Vapaatalo H (2010) Antihypertensive peptides from milk proteins. Pharmaceuticals 3:251–272CrossRef Jäkälä P, Vapaatalo H (2010) Antihypertensive peptides from milk proteins. Pharmaceuticals 3:251–272CrossRef
14.
go back to reference Lunow D, Kaiser S, Rückriemen J, Pohl C, Henle T (2015) Tryptophan-containing dipeptides are C-domain selective inhibitors of angiotensin converting enzyme. Food Chem 166:596–602CrossRef Lunow D, Kaiser S, Rückriemen J, Pohl C, Henle T (2015) Tryptophan-containing dipeptides are C-domain selective inhibitors of angiotensin converting enzyme. Food Chem 166:596–602CrossRef
15.
go back to reference Wei L, Alhenc-Gelas F, Corvol P, Clauser E (1991) The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 266:9002–9008 Wei L, Alhenc-Gelas F, Corvol P, Clauser E (1991) The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 266:9002–9008
16.
go back to reference Elisseeva YE, Kugaevskaya EV (2009) Structure and physiological importance of angiotensin converting enzyme domains. Biomed Chem 3:237–247 Elisseeva YE, Kugaevskaya EV (2009) Structure and physiological importance of angiotensin converting enzyme domains. Biomed Chem 3:237–247
17.
go back to reference Dicpinigaitis PV (2006) Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 129:169–173CrossRef Dicpinigaitis PV (2006) Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 129:169–173CrossRef
18.
go back to reference Khedr S, Martin M, Deussen A (2015) Inhibitory efficacy and biological variability of tryptophan containing dipeptides on human plasma angiotensin converting enzyme activity. J. Hypertens 4:2–6 (open access) Khedr S, Martin M, Deussen A (2015) Inhibitory efficacy and biological variability of tryptophan containing dipeptides on human plasma angiotensin converting enzyme activity. J. Hypertens 4:2–6 (open access)
19.
go back to reference Gee NS, Kenny AJ (1987) Proteins of the kidney microvillar membrane. Enzymic and molecular properties of aminopeptidase W. Biochem J 246:97–102CrossRef Gee NS, Kenny AJ (1987) Proteins of the kidney microvillar membrane. Enzymic and molecular properties of aminopeptidase W. Biochem J 246:97–102CrossRef
20.
go back to reference Jaffe EA, Nachman RL, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52:2745–2756CrossRef Jaffe EA, Nachman RL, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52:2745–2756CrossRef
21.
22.
go back to reference Martin M, Kopaliani I, Jannasch A, Mund C, Todorov V, Henle T, Deussen A (2015) Antihypertensive and cardioprotective effects of the dipeptide isoleucine-tryptophan and whey protein hydrolysate. Acta Physiol 215:167–176. doi:10.1111/apha.12578 Martin M, Kopaliani I, Jannasch A, Mund C, Todorov V, Henle T, Deussen A (2015) Antihypertensive and cardioprotective effects of the dipeptide isoleucine-tryptophan and whey protein hydrolysate. Acta Physiol 215:167–176. doi:10.​1111/​apha.​12578
24.
go back to reference Wu SJ, Soulez M, Yang YH, Chu CS, Shih SC, Hébert MJ, Kuo MC, Hsieh YJ (2015) Local augmented angiotensinogen secreted from apoptotic vascular endothelial cells is a vital mediator of vascular remodelling. PLoS One 10(7):e0132583. doi:10.1371/journal.phone.0132583 Wu SJ, Soulez M, Yang YH, Chu CS, Shih SC, Hébert MJ, Kuo MC, Hsieh YJ (2015) Local augmented angiotensinogen secreted from apoptotic vascular endothelial cells is a vital mediator of vascular remodelling. PLoS One 10(7):e0132583. doi:10.​1371/​journal.​phone.​0132583
25.
go back to reference FitzGerald RJ, Murray BA, Walsh DJ (2004) Hypotensive peptides from milkproteins. J Nutr 134:980S–988 S CrossRef FitzGerald RJ, Murray BA, Walsh DJ (2004) Hypotensive peptides from milkproteins. J Nutr 134:980S–988 S CrossRef
27.
go back to reference Foltz M, Cerstiaens A, van Meensel A, Mols R, van der Pijl P.C, Duchateau G, Augustijns P. (2008) The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro and Val-Pro-Pro show increasing permeabilities with increasing physiological relevance of absorption models. Peptides 29:1312–1320 (supplementary data) CrossRef Foltz M, Cerstiaens A, van Meensel A, Mols R, van der Pijl P.C, Duchateau G, Augustijns P. (2008) The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro and Val-Pro-Pro show increasing permeabilities with increasing physiological relevance of absorption models. Peptides 29:1312–1320 (supplementary data) CrossRef
28.
go back to reference Kopaliani I, Martin M, Zatschler B, Müller B, Deussen A (2016) Whey peptide Isoleucine-Tryptophan inhibits expression and activity of matrix metalloproteinase-2 in rat aorta. Peptides 82:52–59CrossRef Kopaliani I, Martin M, Zatschler B, Müller B, Deussen A (2016) Whey peptide Isoleucine-Tryptophan inhibits expression and activity of matrix metalloproteinase-2 in rat aorta. Peptides 82:52–59CrossRef
Metadata
Title
Effects of tryptophan-containing peptides on angiotensin-converting enzyme activity and vessel tone ex vivo and in vivo
Authors
Sherif Khedr
Andreas Deussen
Irakli Kopaliani
Birgit Zatschler
Melanie Martin
Publication date
01-04-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 3/2018
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-016-1374-y

Other articles of this Issue 3/2018

European Journal of Nutrition 3/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.